Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Diagnosis of indolent B-cell non-Hodgkin's lymphoma of 1 of the following subtypes: Follicular (grade 1, 2, or 3) Marginal zone (extranodal, nodal, or splenic) CD20-positive disease Relapsed or progressive disease after prior anti-neoplastic therapy, as indicated by 1 of the following: New lesions Objective evidence of progression of existing lesions Complete response ≥ 6 months in duration after prior rituximab therapy* NOTE: *For patients who were previously treated with a regimen that included rituximab At least 1 measurable lymph node mass > 1.5 cm in 2 perpendicular dimensions that has not been irradiated OR that has progressed since prior radiotherapy No active CNS lymphoma PATIENT CHARACTERISTICS: Age 18 and over Performance status Karnofsky 50-100% OR ECOG 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 50,000/mm^3 Hepatic AST and ALT ≤ 3 times upper limit of normal (ULN) Bilirubin ≤ 2 times ULN Renal Creatinine ≤ 2 mg/dL OR Creatinine clearance ≥ 30 mL/min Immunologic No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or to any component of rituximab, including polysorbate 80 and sodium citrate dihydrate No active systemic infection requiring treatment No history of allergic reaction attributable to compounds containing boron or mannitol Other No peripheral neuropathy or neuropathic pain ≥ grade 2 No other malignancy within the past 5 years except completely resected basal cell or squamous cell skin cancer or an in situ malignancy Previously diagnosed prostate cancer allowed provided the following criteria are met: T1-2a, N0, M0 disease AND Gleason score ≤ 7 AND prostate specific antigen (PSA) ≤ 10 ng/mL before initial therapy Treated with definitive curative therapy (i.e., prostatectomy or radiotherapy) within the past 2 years No clinical evidence of prostate cancer AND undetectable PSA (for prostatectomy patients) or PSA < 1 ng/mL (for patients who did not undergo prostatectomy) No serious medical or psychiatric illness that would preclude study participation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics More than 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., ibritumomab tiuxetan or iodine I 131 tositumomab) More than 4 weeks since prior rituximab, alemtuzumab, or other unconjugated therapeutic antibody No concurrent prophylactic bone marrow growth factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF], or epoetin alfa) during course 1 of study therapy Chemotherapy More than 6 weeks since prior nitrosoureas No concurrent cisplatin Endocrine therapy No concurrent corticosteroids (e.g., dexamethasone) except prednisone ≤ 15 mg/day or equivalent for adrenal insufficiency Radiotherapy See Disease Characteristics See Biologic therapy More than 3 weeks since prior radiotherapy No concurrent radiotherapy Surgery More than 2 weeks since prior major surgery Other Recovered from all prior therapy No prior bortezomib More than 3 weeks since prior antineoplastic therapy More than 3 weeks since prior experimental therapy No other concurrent antineoplastic therapy No other concurrent investigational agents Concurrent participation in a non-treatment study allowed provided it does not interfere with participation in this study